WO2024081775A1 - Synthesis of 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds - Google Patents
Synthesis of 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds Download PDFInfo
- Publication number
- WO2024081775A1 WO2024081775A1 PCT/US2023/076675 US2023076675W WO2024081775A1 WO 2024081775 A1 WO2024081775 A1 WO 2024081775A1 US 2023076675 W US2023076675 W US 2023076675W WO 2024081775 A1 WO2024081775 A1 WO 2024081775A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- refers
- yield
- mmol
- reacting
- Prior art date
Links
- 238000003786 synthesis reaction Methods 0.000 title abstract description 16
- 230000015572 biosynthetic process Effects 0.000 title abstract description 15
- -1 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds Chemical class 0.000 title description 15
- 239000007806 chemical reaction intermediate Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 38
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 14
- 230000002194 synthesizing effect Effects 0.000 claims description 10
- 239000000543 intermediate Substances 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 8
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 150000007529 inorganic bases Chemical class 0.000 claims description 5
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 claims description 4
- PDVFSPNIEOYOQL-UHFFFAOYSA-N (4-methylphenyl)sulfonyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OS(=O)(=O)C1=CC=C(C)C=C1 PDVFSPNIEOYOQL-UHFFFAOYSA-N 0.000 claims description 4
- GNDKYAWHEKZHPJ-UHFFFAOYSA-N 2-nitrobenzenesulfonimidic acid Chemical compound NS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O GNDKYAWHEKZHPJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 claims description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 4
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 229940125773 compound 10 Drugs 0.000 claims 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 1
- 102100030122 Protein O-GlcNAcase Human genes 0.000 abstract description 11
- 108010045982 hexosaminidase C Proteins 0.000 abstract description 11
- 239000003112 inhibitor Substances 0.000 abstract description 9
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- AURNCCDRERCCJY-UHFFFAOYSA-N [6-chloro-2-(hydroxymethyl)pyridin-3-yl]methanol Chemical compound OCC1=CC=C(Cl)N=C1CO AURNCCDRERCCJY-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- MSLXPRCFQNRAPN-UHFFFAOYSA-N 2-chloro-6,7-dihydro-5h-pyrrolo[3,4-b]pyridine Chemical compound ClC1=CC=C2CNCC2=N1 MSLXPRCFQNRAPN-UHFFFAOYSA-N 0.000 description 4
- LKDXOWCTMJUUCN-UHFFFAOYSA-N 2-chloro-6-[(2,4-dimethoxyphenyl)methyl]-5,7-dihydropyrrolo[3,4-b]pyridine Chemical compound ClC1=CC=C2C(=N1)CN(C2)CC1=C(C=C(C=C1)OC)OC LKDXOWCTMJUUCN-UHFFFAOYSA-N 0.000 description 4
- XQMVICDINIHBII-UHFFFAOYSA-N 6-chloro-2,3-bis(chloromethyl)pyridine Chemical compound ClCC1=CC=C(Cl)N=C1CCl XQMVICDINIHBII-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 208000034799 Tauopathies Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- RRZMDTAIYFPMKV-SUNYJGFJSA-N 1-[2-[(3R,5S)-1-[(1S)-1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethyl]-5-methylpyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl]ethanone Chemical compound FC1=CC2=C(N=C(S2)C)C=C1[C@H](C)N1C[C@@H](C[C@@H]1C)OC1=CC=C2C(=N1)CN(C2)C(C)=O RRZMDTAIYFPMKV-SUNYJGFJSA-N 0.000 description 2
- CWLUFVAFWWNXJZ-UHFFFAOYSA-N 1-hydroxypyrrolidine Chemical compound ON1CCCC1 CWLUFVAFWWNXJZ-UHFFFAOYSA-N 0.000 description 2
- HQULYFAKUZDRPB-UHFFFAOYSA-N 6-bromo-2-[4-(trifluoromethoxy)phenoxy]-1,3-benzothiazole Chemical compound BrC1=CC2=C(N=C(S2)OC2=CC=C(C=C2)OC(F)(F)F)C=C1 HQULYFAKUZDRPB-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 229940126137 O-GlcNAcase inhibitor Drugs 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000002511 neuropil thread Anatomy 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- PPAIMZHKIXDJRN-FMDGEEDCSA-N (3ar,5r,6s,7r,7ar)-2-(ethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O PPAIMZHKIXDJRN-FMDGEEDCSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- CKGWOWOYZAFRJY-UHFFFAOYSA-N 1-(2-chloro-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl)ethanone Chemical compound ClC1=CC=C2C(=N1)CN(C2)C(C)=O CKGWOWOYZAFRJY-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OVAWAJRNDPSGHE-UHFFFAOYSA-N 2-methyloxolane;hydrate Chemical compound O.CC1CCCO1 OVAWAJRNDPSGHE-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000003316 glycosidase inhibitor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
Definitions
- the present invention relates to novel methods of synthesizing 6-fluoro-2- methylbenzo[d]thiazol-5-yl compounds, and to intermediates useful in the synthesis of the compounds.
- the present invention is in the field of synthetic organic chemistry.
- AD Alzheimer’s disease
- the oligomerization of the microtubule-associated protein tau into filamentous structures such as paired helical filaments (PHFs) and straight or twisted filaments, which give rise to neurofibrillary tangles (NFTs) and neuropil threads (NTs), is one of the defining pathological features of AD and other tauopathies.
- the number of NFTs in the brains of individuals with AD has been found to correlate closely with the severity of the disease, suggesting tau has a key role in neuronal dysfunction and neurodegeneration (Nelson et al., J Neuropathol Exp Neurol., 71(5), 362-381(2012)).
- Tau pathology has been shown to correlate with disease duration in PSP in that cases with a more aggressive disease course have a higher tau burden than cases with a slower progression. (Williams et al., Brain, 130, 1566-76 (2007)).
- OGA inhibitors are recognized as a viable therapeutic approach to reduce the accumulation of hyperphosphorylated, pathological forms of tau.
- US 2017/0298082 discloses certain glycosidase inhibitors useful in treating tauopathies such as AD.
- WO 2018/109198 Al and WO 2018/109202 Al disclose certain
- OGA inhibitors useful for treating tauopathies such as AD and PSP.
- W02020/068530 provides compounds that are potent inhibitors of OGA, including those with the potential to be sufficiently brain penetrant to effectively treat tauopathies, such as AD and PSP.
- the present invention provides improved synthetic routes for the synthesis of molecules useful as OGA inhibitors, and compounds representing synthetic intermediates thereof.
- the present application provides a compound, which is: and methods of synthesis thereof.
- the present application also provides a compound, which is: and methods of synthesis thereof.
- the present application also provides a compound, which is: and methods of synthesis thereof.
- the present application also provides a method of synthesizing a compound: which includes a step of reacting a first compound with p-toluenesulfonic anhydride to yield a second compound .
- This reaction may also include 2- methyltetrahydrofuran and triethylamine.
- the second compound above may be reacted with 2- nitrobenzenesulfonamide and an inorganic base to yield a third compound
- the method may further include reacting the third compound above with 1 -dodecanethiol and an inorganic base, and subsequently reacting with acetic anhydride, to yield the compound
- the present application also provides a method of synthesizing a compound of Formula (I) wherein X is hydrogen or methyl, which method includes a reaction intermediate generated by any one of the previously- described steps.
- the present disclosure furthermore provides a method of synthesizing a compound of Formula (I)
- the present disclosure contemplates all individual enantiomers and diasteromers, as well as mixtures of the enantiomers of said compounds, including racemates.
- the compounds of the present invention, or salts thereof, may be prepared by a variety of procedures known to one of ordinary skill in the art, some of which are illustrated in the schemes, preparations, and examples below.
- the products of each step in the schemes below can be recovered by conventional methods well known in the art, including extraction, evaporation, precipitation, chromatography, filtration, trituration, and crystallization.
- all substituents unless otherwise indicated, are as previously defined.
- the reagents and starting materials are readily available to one of ordinary skill in the art. Without limiting the scope of the invention, the following schemes, preparations, and examples are provided to further illustrate the invention.
- compounds of the present disclosure may be prepared by using starting material or intermediate with the corresponding desired stereochemical configuration which can be prepared by one of skill in the art.
- ACN or “MeCN” refers to acetonitrile
- Ac refers to acetyl
- AcOH refers to acetic acid
- AC2O acetic anhydride
- BOC refers to te/7-butoxycarbonyl
- CBz refers to carbonylbenzyloxy
- DCM methylene chloride or dichloromethane
- DIPEA diisopropylethylamine
- DMEA refers to dimethylethylamine
- DMF refers to N,N- dimethylformamide
- DMSO refers to dimethyl sulfoxide
- dppf ’ refers to diphenylphosphinoferrocene
- EDTA refers to ethylenediaminetetraacetic acid
- Scheme 1 provides a method for preparing l-(2-chloro-5,7-dihydro-6H-pyrrolo[3,4- b]pyridin-6-yl)ethan-l-one from (6-chloropyridine-2,3-diyl)dimethanol.
- the alcohol moi eties may be converted to halides through a substitution reaction, such as by using thionyl chloride, oxalyl chloride or a similar chlorinating reagent.
- the mixture may be stirred and concentrated under reduced pressure to yield 6-chloro-2,3- bis(chloromethyl)pyridine.
- a non-nucleophilic base such as DIPEA and (2,4- dimethoxyphenyl)methanamine may be added to a solution of 6-chloro-2,3- bis(chloromethyl)pyridine in a suitable solvent (such as dichloromethane).
- a suitable solvent such as dichloromethane
- the mixture is stirred (in one aspect, at room temperature for about 72 h) after which it is diluted with the same or a different organic solvent (in this instance, dichloromethane) and washed with water (200 mb).
- the aqueous layer may then be extracted with organic solvent, as is well known in the art, and the combined organic layers may then be dried, such as over sodium sulfate.
- the resultant residue may be subjected to a chromatographic process (such as passage through silica gel), and eluted using a variety of solvent systems well know by one skilled in the art (in one aspect, with ethyl acetate/hexanes) to yield 2-chloro-6-(2,4-dimethoxybenzyl)-6,7-dihydro-5H-pyrrolo[3,4- b]pyridine.
- a chromatographic process such as passage through silica gel
- solvent systems well know by one skilled in the art (in one aspect, with ethyl acetate/hexanes) to yield 2-chloro-6-(2,4-dimethoxybenzyl)-6,7-dihydro-5H-pyrrolo[3,4- b]pyridine.
- 2-chloro-6-(2,4-dimethoxybenzyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine may be mixed with anisole in the presence of an appropriate acid (in one aspect, trifluoroacetic acid).
- the mixture may be refluxed for an amount of time, for instance, 1 to 1.5 hours, and concentrated to obtain a residue which upon work-up using an aprotic solvent and subsequent basicifi cation with sodium carbonate may afford 2-chloro-6,7-dihydro-5H- pyrrolo[3,4-b]pyridine, which may be purified as is known in the art.
- step D acetylation of 2-chloro-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine may be accomplished using acetic anhydride to yield the final product, l-(2-chl oro-5, 7-dihydro-6H- pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one.
- Precipitation may be achieved by addition of a salt (such as sodium chloride), and the compound may be purified by conventional processes.
- Scheme 2 likewise provides a method for preparing l-(2-chloro-5,7-dihydro-6H- pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one from (6-chloropyridine-2,3-diyl)dimethanol, and provides an alternate way to synthesize the desired compound.
- step A (6-chloropyridine-2,3-diyl)dimethanol may be combined with 2- methyltetrahydrofuran, an amine base such as triethylamine, and p-toluenesulfonic anhydride, stirred, and quenched with saturated aqueous sodium bicarbonate solution, to yield the tosylated product.
- an amine base such as triethylamine
- p-toluenesulfonic anhydride stirred, and quenched with saturated aqueous sodium bicarbonate solution
- saturated aqueous sodium bicarbonate solution saturated aqueous sodium bicarbonate solution
- step B (6-chloropyridine-2,3-diyl)bis(methylene) bis(4-methylbenzenesulfonate) and 2-nitrobenzenesulfonamide are combined in organic solvent (such as acetonitrile).
- organic solvent such as acetonitrile
- an inorganic base such as cesium carbonate
- an organic solvent such as acetonitrile
- step C to the foregoing mixture is added 1 -dodecanethiol and a carbonate base such as cesium carbonate.
- a carbonate base such as cesium carbonate.
- the mixture is stirred and heated, then cooled and filtered. Solids were collected and washed with a non-polar solvent (such as MTBE).
- the solid is then combined with water and 2-methyltetrahydrofuran, stirred, and extracted, filtered, and concentrated by methods well known in the art, to yield 1 -(2-chl oro-5, 7-dihydro-6H- pyrrolo[3,4-b]pyridin-6-yl)ethan- 1 -one.
- Step B A solution of (6-chloropyridine-2,3-diyl)bis(methylene) bis(4- methylbenzenesulfonate) (34.2 g, 66.7 mmol) and 2-nitrobenzenesulfonamide (14.8 g, 73.2 mmol) was prepared in acetonitrile (342 mL) [Solution 1], Separately, a suspension of cesium carbonate was prepared (43.5 g, 134 mmol) in acetonitrile (342 mL) [Solution 2], Solution 1 was added to Solution 2 at room temperature dropwise at a rate of 1 mL/min.
- Step C To the foregoing mixture was added 1 -dodecanethiol (24.5 mL, 100 mmol) and cesium carbonate (43.5 g, 134 mmol) in one portion. The mixture was stirred at 75 °C for 4.5 h, then cooled to room temperature and filtered. Solids were collected and washed with MTBE (2 x 50 mL). The solid was then combined with water (150 mL) and 2- methyltetrahydrofuran (150 mL). This mixture was stirred at room temperature for 5 min, and the resulting layers separated. To the aqueous layer was added acetic anhydride (9.46 mL, 100 mmol).
- Schemes 1 and 2 provide novel and improved synthetic routes for the synthesis of 1- (2-chloro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l -one, relative to previous routes.
- this compound is useful as an intermediate for the synthesis of OGA inhibitors.
- OGA inhibitors are disclosed in International Patent Publication No. W02020/068530, and corresponding United States Patents No. 10,752,632 and 10,836,773, all of which are hereby incorporated by reference in their entirety, as is data demonstrating their efficacy as OGA inhibitors.
- l-(2-chloro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one may be used to synthesize an OGA inhibitor of Formula (I) below:
- X is H or methyl.
- step A shows nucleophilic aromatic substitution of l-(2-chloro-5,7- dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one with an appropriately N-protected commercially available hydroxypyrrolidine.
- N-protecting groups such as Boc, CBz, benzyl, or methyl, as needed for ease of removal.
- about 1 equivalent of the appropriately N-protected 4-hydroxy-2-methylpyrrolidine may be treated with about 2 equivalents of a suitable strong base, such as NaH, KO-t-Bu, or NaO-/-Bu, in an suitable polar solvent, such as THF, DMF, 1,4-di oxane, or DMSO, at about 0 °C to about RT.
- a suitable strong base such as NaH, KO-t-Bu, or NaO-/-Bu
- an suitable polar solvent such as THF, DMF, 1,4-di oxane, or DMSO
- about 1.2 equivalents of the desired acylated product of Scheme 1, step A may be added at about 0 °C to about RT, and the resulting mixture may be stirred at about RT for about 12-24 h.
- the resulting reaction product may be isolated by techniques well known in the art, such as extraction and chromatography.
- the reaction mixture may be diluted with water, extracted with an appropriate organic solvent, such as DCM or EtOAc, and the combined organic extracts may be washed sequentially with water, saturated aqueous NaCl, dried over a suitable drying agent, such as NaiSCU or MgSCU, filtered, and the filtrate may be concentrated under reduced pressure.
- the resulting residue may be purified by flash chromatography over silica, using a suitable mixture of polar and non-polar organic solvents, such as EtOAc or acetone in hexanes, to obtain the desired product of Scheme 3, step A.
- a suitable mixture of polar and non-polar organic solvents such as EtOAc or acetone in hexanes
- step B the skilled artisan will recognize the removal of the protecting group may be accomplished under an array of conditions well known in the art.
- PG BOC
- the product of Scheme 3 may be dissolved in a suitable organic solvent, such as DCM, and treated with an appropriate acid, such as HC1 dissolved in an organic solvent (e.g., Et2O, 1,4-di oxane), or TFA, and the resulting reaction mixture may be stirred at about RT to about 80 °C from about 30 min to 8 h.
- the resulting reaction product may be isolated by techniques well known in the art, such as evaporation.
- the reaction mixture may be subjected to concentration under reduced pressure to obtain the HC1 salt of the product of Scheme 3, step B.
- step C N-C bond formation may be accomplished under a variety of methods well known in the art, including nucleophilic displacement of an alkyl halide, transition-metal catalysis, or under reductive amination conditions.
- an appropriately substituted aldehyde such as 6-fluoro-2-methyl-l,3- benzothiazole-5-carbaldehyde and about 1 equivalent of the deprotected pyrrolidine hydrochloride (the product of Scheme 3, step B) may be dissolved in a suitable organic solvent, such as DCM, and the resulting solution may be treated with about 2.5-2.75 equivalents of a non-nucleophilic base, such as DIPEA or TEA for about 30 min to about 1 h.
- DIPEA a non-nucleophilic base
- a suitable borohydride reducing agent such as sodium borohydride, sodium tri(acetoxy)borohydride, or sodium cyanoborohydride
- the resulting mixture may be stirred at about RT for about 12 to 24 h.
- the resulting reaction product may be isolated by techniques well known in the art, such as extraction and column chromatography. For example, the reaction mixture may be quenched slowly with a saturated aqueous mild basic solution, such as Nal lCO;.
- the resulting mixture may be extracted with a suitable organic solvent, such as DCM or EtOAc, and the combined organic extracts may be washed sequentially with water, saturated aqueous NaCl, dried over a suitable drying agent, such as NaiSCh or MgSCh, filtered, and the filtrate may be concentrated under reduced pressure.
- a suitable organic solvent such as DCM or EtOAc
- the combined organic extracts may be washed sequentially with water, saturated aqueous NaCl, dried over a suitable drying agent, such as NaiSCh or MgSCh, filtered, and the filtrate may be concentrated under reduced pressure.
- the resulting residue may be purified by flash chromatography over silica, using a suitable mixture of polar and non-polar organic solvents, such as EtOAc or acetone in hexanes, or methanol in DCM or EtOAc, to obtain the title compound.
- step C To a solution of 6-fluoro-2-methyl-l,3-benzothiazole-5- carbaldehyde (0.19 g, 0.95 mmol) and l-(2-(((3R,5S)-5-methylpyrrolidin-3-yl)oxy)-5,7- dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one hydrochloride (0.28 g, 0.94 mmol) in DCM (9 mb) is added DTPEA (0.45 mL, 2.6 mmol). The resulting solution is stirred at RT for 40 min. To the solution is added NaBH(OAc)3 (0.65 g, 3.04 mmol).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides improved reaction schemes and novel reaction intermediates for the synthesis of molecules useful as O-GlcNAcase (OGA) inhibitors.
Description
SYNTHESIS OF 6-FLUORO-2-METHYLBENZOrD1THIAZOL-5-YL COMPOUNDS
The present invention relates to novel methods of synthesizing 6-fluoro-2- methylbenzo[d]thiazol-5-yl compounds, and to intermediates useful in the synthesis of the compounds. The present invention is in the field of synthetic organic chemistry.
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that affects millions of patients worldwide. In view of the currently approved agents on the market which afford only transient symptomatic benefits to the patient, there is a significant unmet need in the treatment of AD.
The oligomerization of the microtubule-associated protein tau into filamentous structures such as paired helical filaments (PHFs) and straight or twisted filaments, which give rise to neurofibrillary tangles (NFTs) and neuropil threads (NTs), is one of the defining pathological features of AD and other tauopathies. The number of NFTs in the brains of individuals with AD has been found to correlate closely with the severity of the disease, suggesting tau has a key role in neuronal dysfunction and neurodegeneration (Nelson et al., J Neuropathol Exp Neurol., 71(5), 362-381(2012)). Tau pathology has been shown to correlate with disease duration in PSP in that cases with a more aggressive disease course have a higher tau burden than cases with a slower progression. (Williams et al., Brain, 130, 1566-76 (2007)).
Past studies (Yuzwa et al., Nat Chem Biol, 4(8), 483-490 (2008)) support the therapeutic potential of O-GlcNAcase (OGA) inhibitors to limit tau hyperphosphorylation, and aggregation into pathological tau, for the treatment of AD and related tau-mediated neurodegeneration disorders. More recently, the OGA inhibitor Thiamet-G has been linked to slowing motor neuron loss in the JNPL3 tau mouse model (Yuzwa et al., Nat Chem Biol, 8, 393-399 (2012)), and to a reduction in tau pathology and dystrophic neurites in the Tg4510 tau mouse model (Graham et al., Neuropharmacology, 19, 307-313 (2014)). Accordingly, OGA inhibitors are recognized as a viable therapeutic approach to reduce the accumulation of hyperphosphorylated, pathological forms of tau.
US 2017/0298082 discloses certain glycosidase inhibitors useful in treating tauopathies such as AD. WO 2018/109198 Al and WO 2018/109202 Al disclose certain
OGA inhibitors useful for treating tauopathies, such as AD and PSP. W02020/068530 provides compounds that are potent inhibitors of OGA, including those with the potential to be sufficiently brain penetrant to effectively treat tauopathies, such as AD and PSP.
Accordingly, the present invention provides improved synthetic routes for the synthesis of molecules useful as OGA inhibitors, and compounds representing synthetic intermediates thereof.
In particular, the present application provides a compound, which is:
and methods of synthesis thereof.
(b) reacting the second compound with N,N-diisopropylethylamine and (2,4-dimethoxyphenyl)methanamine to yield a third compound
(c) reacting the third compound with anisole and an acid, and subsequently treating with base to yield the compound
The present application also provides a method of synthesizing a compound:
which includes a step of reacting a first compound
with p-toluenesulfonic anhydride to yield a second compound
. This reaction may also include 2- methyltetrahydrofuran and triethylamine.
In a further step, the the second compound above may be reacted with 2- nitrobenzenesulfonamide and an inorganic base to yield a third compound
In yet a further step, the method may further include reacting the third compound above with 1 -dodecanethiol and an inorganic base, and subsequently reacting with acetic anhydride, to yield the compound
The present application also provides a method of synthesizing a compound of Formula (I)
wherein X is hydrogen or methyl, which method includes a reaction intermediate generated by any one of the previously- described steps.
(I), wherein X is hydrogen or methyl,
wherein the method includes an intermediate selected from the group consisting
The present disclosure contemplates all individual enantiomers and diasteromers, as well as mixtures of the enantiomers of said compounds, including racemates.
Individual enantiomers may be separated or resolved by one of ordinary skill in the art at any convenient point in the synthesis of compounds of the invention, by methods such as selective crystallization techniques, chiral chromatography (See for example, J. Jacques, et al., "Enantiomers, Racemates, and Resolutions" , John Wiley and Sons, Inc., 1981, and E.L. Eliel and S.H. Wilen,” Stereochemistry of Organic Compounds'", Wiley-Interscience, 1994), or supercritical fluid chromatography (SFC) (See for example, T. A. Berger; “Supercritical Fluid Chromatography Primer f Agilent Technologies, July 2015).
The compounds of the present invention, or salts thereof, may be prepared by a variety of procedures known to one of ordinary skill in the art, some of which are illustrated in the schemes, preparations, and examples below. The products of each step in the schemes below can be recovered by conventional methods well known in the art, including extraction, evaporation, precipitation, chromatography, filtration, trituration, and crystallization. In the schemes below, all substituents unless otherwise indicated, are as previously defined. The reagents and starting materials are readily available to one of ordinary skill in the art. Without limiting the scope of the invention, the following schemes, preparations, and examples are provided to further illustrate the invention. In addition, one of ordinary skill in the art appreciates that compounds of the present disclosure may be prepared by using starting material or intermediate with the corresponding desired stereochemical configuration which can be prepared by one of skill in the art.
Certain abbreviations are defined as follows: “ACN” or “MeCN” refers to acetonitrile; “Ac” refers to acetyl; “AcOH” refers to acetic acid; “AC2O” refers to acetic
anhydride; “BOC” refers to te/7-butoxycarbonyl; “CBz” refers to carbonylbenzyloxy; “DCM” refers to methylene chloride or dichloromethane; “DIPEA” refers to diisopropylethylamine; “DMEA” refers to dimethylethylamine; “DMF” refers to N,N- dimethylformamide; “DMSO” refers to dimethyl sulfoxide; “dppf ’ refers to diphenylphosphinoferrocene; “EDTA” refers to ethylenediaminetetraacetic acid; “ES-MS” or “ES/MS” refers to Electrospray Mass Spectrometry; “EtOAc” refers to ethyl acetate; “EtOH” refers to ethanol or ethyl alcohol; “h” refers to hour or hours; “K0-/-Bu” refers to potassiumter /-butoxi de; “Me” refers to methyl; “min” refers to minute or minutes; “MeOH” refers to methanol; “MHz” refers to megahertz; “mol” refers to mole or moles; “mmol” refers to millimole or millimoles; “MTBE”: refers to methyl tert-butyl ether; “NaBH(OAc)3” refers to sodium triacetoxyborohydride; “NaO-/-Bu” refers to sodium-te/7-butoxide; “NMR” refers to nuclear magnetic resonance; “OAc” refers to acetate or acetoxy; “PG” refers to protecting group; “RT” refers to room temperature; “TEA” refers to triethylamine; “TFA” refers to trifluoroacetic acid; “THF” refers to tetrahydrofuran; “Ts” refers to tosyl, or toluenesulfonyl; “[OC]D20” refers to specific optical rotation at 20 °C and 589 nm, wherein c is the concentration in g/mL.
Scheme 1 provides a method for preparing l-(2-chloro-5,7-dihydro-6H-pyrrolo[3,4- b]pyridin-6-yl)ethan-l-one from (6-chloropyridine-2,3-diyl)dimethanol. In step A, the alcohol moi eties may be converted to halides through a substitution reaction, such as by using thionyl chloride, oxalyl chloride or a similar chlorinating reagent. The mixture may be
stirred and concentrated under reduced pressure to yield 6-chloro-2,3- bis(chloromethyl)pyridine.
In step B, a non-nucleophilic base such as DIPEA and (2,4- dimethoxyphenyl)methanamine may be added to a solution of 6-chloro-2,3- bis(chloromethyl)pyridine in a suitable solvent (such as dichloromethane). The mixture is stirred (in one aspect, at room temperature for about 72 h) after which it is diluted with the same or a different organic solvent (in this instance, dichloromethane) and washed with water (200 mb). The aqueous layer may then be extracted with organic solvent, as is well known in the art, and the combined organic layers may then be dried, such as over sodium sulfate. After filtration and concentration, the resultant residue may be subjected to a chromatographic process (such as passage through silica gel), and eluted using a variety of solvent systems well know by one skilled in the art (in one aspect, with ethyl acetate/hexanes) to yield 2-chloro-6-(2,4-dimethoxybenzyl)-6,7-dihydro-5H-pyrrolo[3,4- b]pyridine.
In step C, 2-chloro-6-(2,4-dimethoxybenzyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine may be mixed with anisole in the presence of an appropriate acid (in one aspect, trifluoroacetic acid). The mixture may be refluxed for an amount of time, for instance, 1 to 1.5 hours, and concentrated to obtain a residue which upon work-up using an aprotic solvent and subsequent basicifi cation with sodium carbonate may afford 2-chloro-6,7-dihydro-5H- pyrrolo[3,4-b]pyridine, which may be purified as is known in the art.
In step D, acetylation of 2-chloro-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine may be accomplished using acetic anhydride to yield the final product, l-(2-chl oro-5, 7-dihydro-6H- pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one. Precipitation may be achieved by addition of a salt (such as sodium chloride), and the compound may be purified by conventional processes.
Alternative synthesis of l-(2-chloro-5,7-dihydro-6H-pyrrolor3,4-b1pyridin-6-yl)ethan-l-one
Scheme 2 likewise provides a method for preparing l-(2-chloro-5,7-dihydro-6H- pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one from (6-chloropyridine-2,3-diyl)dimethanol, and provides an alternate way to synthesize the desired compound.
In step A, (6-chloropyridine-2,3-diyl)dimethanol may be combined with 2- methyltetrahydrofuran, an amine base such as triethylamine, and p-toluenesulfonic anhydride, stirred, and quenched with saturated aqueous sodium bicarbonate solution, to yield the tosylated product. To isolate (6-chloropyridine-2,3-diyl)bis(methylene) bis(4- methylbenzenesulfonate), the mixture may be filtered, extracted with a non-polar solvent (such as MTBE) and the layers separated. The organic layers are combined and may be washed with brine prior to drying, filtration, and concentration, as is well known in the art, to yield the product.
In step B, (6-chloropyridine-2,3-diyl)bis(methylene) bis(4-methylbenzenesulfonate) and 2-nitrobenzenesulfonamide are combined in organic solvent (such as acetonitrile). Separately, an inorganic base (such as cesium carbonate) is suspended in an organic solvent, (again, such as acetonitrile), and the first solution is added dropwise to the second and mixed. This yields 2-chloro-6-((2-nitrophenyl)sulfonyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine.
In step C, to the foregoing mixture is added 1 -dodecanethiol and a carbonate base such as cesium carbonate. The mixture is stirred and heated, then cooled and filtered. Solids were collected and washed with a non-polar solvent (such as MTBE). The solid is then combined with water and 2-methyltetrahydrofuran, stirred, and extracted, filtered, and concentrated by methods well known in the art, to yield 1 -(2-chl oro-5, 7-dihydro-6H- pyrrolo[3,4-b]pyridin-6-yl)ethan- 1 -one.
Preparation 1 (Example 1)
Scheme 1, Step A: (6-Chloropyridine-2.3-divl)dimethanol (34.9 g, 201 mmol) was added portion wise to thionyl chloride (210 mL, 2.88 mol) which had been cooled to 0 °C. The mixture was stirred at room temperature for 16 h, then concentrated under reduced pressure to give 6-chloro-2,3-bis(chloromethyl)pyridine (43.7 g, 201 mmol).
Scheme 1, Step B: A solution of 6-chloro-2,3-bis(chloromethyl)pyridine (43.7 g, 201 mmol) in dichloromethane (115 mL) was cooled to 0 °C. To this was slowly added N,N- diisopropylethylamine (110 mL, 631 mmol) and (2,4-dimethoxyphenyl)methanamine (33.0 mL, 220 mmol), keeping the internal temperature below 15 °C. The mixture was stirred at room temperature for 72 h, after which it was diluted with dichloromethane (200 mL) and washed with water (200 mL). The aqueous layer was extracted with dichloromethane (2 x 100 mL). The combined organic layers were then dried over sodium sulfate, fdtered, and concentrated under reduced pressure. The resultant residue was dissolved in dichloromethane
(100 mL) and passed through silica gel (600 mL), followed by elution with ethyl acetate (1.4 L). The eluent was concentrated under reduced pressure to give 41.4 g of the title compound (68% over two steps). ES-MS m/z 305 (M+H).
(400 MHz, CDCh) 5 7.40 (d, J= 8 Hz, 1H), 7.24 (d, J= 9 Hz, 1H), 7.11 (d, J= 8 Hz, 1H), 6.48 (m, 2H), 4.00 (bs, 2H), 3.94 (bs, 2H), 3.88 (s, 2H), 3.82 (s, 3H), 3.81 (s, 3H).
Scheme 1, Step C: A mixture of 2-chloro-6-(2,4-dimethoxybenzyl)-6,7-dihydro-5H- pyrrolo[3,4-b]pyridine (41.4 g, 136 mmol), anisole (16.3 mL, 150 mmol), and trifluoroacetic acid (100 mL) was heated at reflux for 1 h 15 min, then concentrated under reduced pressure. The residue obtained was dissolved in ethyl acetate (200 mL) and washed with water (200 mL). The aqueous layer was adjusted to pH = 8 with solid sodium carbonate to afford an aqueous solution of 2-chloro-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine (21.0 g, 136 mmol). ESMS m/z 155 (M+H).
Scheme 1, Step D: To the solution of 2-chloro-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine (21.0 g, 136 mmol) was added acetic anhydride (19.3 mL, 204 mmol). The mixture was stirred at room temperature for 10 min. The pH of the solution was adjusted to pH = 8 with solid sodium carbonate. The mixture was filtered, sodium chloride (100 g) was added to the filtrate, and the mixture was stirred at room temperature. The resulting solid was collected by vacuum filtration and washed with water (1 x 20 mL). All aqueous layers were combined and extracted with di chloromethane (2 x 300 mL). The previously collected solid was combined
with the organic extracts and dried over magnesium sulfate, fdtered, and concentrated under reduced pressure to give the title compound (13.0 g, 48% over two steps). ES-MS m/z 197 (M+H).
Alternative synthesis of l -(2-chloro-5,7-dihydro-6H-pyrrolor3,4-b1pyridin-6-yl)ethan-l-one
Preparation 3 (Example 2)
Scheme 2, Step A: To a mixture of (6-chloropyridine-2,3-diyl)dimethanol (12.4 g, 71.3 mmol), 2-methyltetrahydrofuran (186 mL), and triethylamine (29.8 m , 214 mmol) at room temperature was added p-toluenesulfonic anhydride (58.2 g, 178 mmol) in six equal portions over 60 min. The mixture was stirred at room temperature for 4.5 h. The reaction was then quenched with saturated aqueous sodium bicarbonate solution (150 mL), and the mixture filtered through celite, which was rinsed with water (30 mL) and MTBE (30 mL). The resulting layers were separated, and the aqueous layer was extracted with MTBE (2 x 100 mL). All organic layers were combined and washed with brine (150 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was azeotroped with MeCN (2 x 50 mL) to give the title compound (34.2 g, 94%). ES-MS m/z 482 (M+H). lH NMR (400 MHz, CDCh) 8 7.79 (d, J= 8 Hz, 2H), 7.74 (d,
J= 8 Hz, 2H), 7.66 (d, J= 8 Hz, 1H), 7.37 (d, J= 8 Hz, 2H), 7.32 (d, J= 8 Hz, 2H), 7.27 (d, J= 8 Hz, 1H), 5.14 (s, 2H), 5.07 (s, 2H), 2.47 (s, 3H), 2.45 (s, 3H).
Scheme 2, Step B: A solution of (6-chloropyridine-2,3-diyl)bis(methylene) bis(4- methylbenzenesulfonate) (34.2 g, 66.7 mmol) and 2-nitrobenzenesulfonamide (14.8 g, 73.2 mmol) was prepared in acetonitrile (342 mL) [Solution 1], Separately, a suspension of cesium carbonate was prepared (43.5 g, 134 mmol) in acetonitrile (342 mL) [Solution 2], Solution 1 was added to Solution 2 at room temperature dropwise at a rate of 1 mL/min. The mixture was stirred at room temperature for 17 h to give crude 2-chloro-6-((2- nitrophenyl)sulfonyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine. ES-MS m/z 340 (M+H).
Scheme 2. Step C: To the foregoing mixture was added 1 -dodecanethiol (24.5 mL, 100 mmol) and cesium carbonate (43.5 g, 134 mmol) in one portion. The mixture was stirred at 75 °C for 4.5 h, then cooled to room temperature and filtered. Solids were collected and washed with MTBE (2 x 50 mL). The solid was then combined with water (150 mL) and 2- methyltetrahydrofuran (150 mL). This mixture was stirred at room temperature for 5 min, and the resulting layers separated. To the aqueous layer was added acetic anhydride (9.46 mL, 100 mmol). This mixture was stirred at room temperature for 5 min, then diluted with 15% aqueous sodium sulfate solution and extracted with 2-methyltetrahydrofuran (4 x 150 mL), followed by extraction with ethyl acetate (2 x 150 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was combined with 1 :4 isopropyl acetate: heptane (78 mL). This mixture was stirred at 50 °C for 45 min, then at room temperature for 15 min. The solid was collected by vacuum
filtration to give the title compound (8.9 g, 66% over two steps). ES-MS m/z 197 (M+H). 1H NMR (400 MHz, d6-DMSO) 5 7.86 (d, J = 8 Hz, 1H), 7.45 (d, J = 8 Hz, 1H), 4.83 (d, J = 11.5 Hz, 2H), 4.59 (d, J= 17 Hz, 2H), 2.06 (app d, J= 1.5 Hz, 3H).
Schemes 1 and 2 provide novel and improved synthetic routes for the synthesis of 1- (2-chloro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l -one, relative to previous routes.
In some aspects, this compound is useful as an intermediate for the synthesis of OGA inhibitors. Certain of these OGA inhibitors are disclosed in International Patent Publication No. W02020/068530, and corresponding United States Patents No. 10,752,632 and 10,836,773, all of which are hereby incorporated by reference in their entirety, as is data demonstrating their efficacy as OGA inhibitors.
Specifically, l-(2-chloro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one may be used to synthesize an OGA inhibitor of Formula (I) below:
In a compound of Formula (I), X is H or methyl.
Such syntheses are described in the patent documents incorporated above, and are recapitulated herein.
Scheme 3 illustrates the synthesis of the compound of Formula (I) when X = H: l-(2- (((3R,5S)-l-((6-fluoro-2-methylbenzo[d]thiazol-5-yl)methyl)-5-methylpyrrolidin-3-yl)oxy)- 5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one.
Scheme 3, step A, shows nucleophilic aromatic substitution of l-(2-chloro-5,7- dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one with an appropriately N-protected commercially available hydroxypyrrolidine. The skilled artisan will recognize that a wide array of nucleophilically-stable N-protecting groups may be used, such as Boc, CBz, benzyl, or methyl, as needed for ease of removal. For example, about 1 equivalent of the appropriately N-protected 4-hydroxy-2-methylpyrrolidine may be treated with about 2 equivalents of a suitable strong base, such as NaH, KO-t-Bu, or NaO-/-Bu, in an suitable polar solvent, such as THF, DMF, 1,4-di oxane, or DMSO, at about 0 °C to about RT. About 1.2 equivalents of the desired acylated product of Scheme 1, step A, may be added at about 0 °C to about RT, and the resulting mixture may be stirred at about RT for about 12-24 h. The resulting reaction product may be isolated by techniques well known in the art, such as extraction and chromatography. For example, the reaction mixture may be diluted with water, extracted with an appropriate organic solvent, such as DCM or EtOAc, and the combined organic extracts may be washed sequentially with water, saturated aqueous NaCl, dried over a suitable drying agent, such as NaiSCU or MgSCU, filtered, and the filtrate may be
concentrated under reduced pressure. The resulting residue may be purified by flash chromatography over silica, using a suitable mixture of polar and non-polar organic solvents, such as EtOAc or acetone in hexanes, to obtain the desired product of Scheme 3, step A. The skilled artisan will recognize that different isomers (e. ., cis- or trans-) of the commercially available hydroxypyrrolidine will give different isomers of the product of Scheme 3, step A.
In Scheme 3, step B, the skilled artisan will recognize the removal of the protecting group may be accomplished under an array of conditions well known in the art. For example, wherein PG = BOC, the product of Scheme 3, step A may be dissolved in a suitable organic solvent, such as DCM, and treated with an appropriate acid, such as HC1 dissolved in an organic solvent (e.g., Et2O, 1,4-di oxane), or TFA, and the resulting reaction mixture may be stirred at about RT to about 80 °C from about 30 min to 8 h. The resulting reaction product may be isolated by techniques well known in the art, such as evaporation. For example, the reaction mixture may be subjected to concentration under reduced pressure to obtain the HC1 salt of the product of Scheme 3, step B.
In Scheme 3, step C, N-C bond formation may be accomplished under a variety of methods well known in the art, including nucleophilic displacement of an alkyl halide, transition-metal catalysis, or under reductive amination conditions. For example, about 1 equivalent of an appropriately substituted aldehyde, such as 6-fluoro-2-methyl-l,3- benzothiazole-5-carbaldehyde and about 1 equivalent of the deprotected pyrrolidine hydrochloride (the product of Scheme 3, step B) may be dissolved in a suitable organic solvent, such as DCM, and the resulting solution may be treated with about 2.5-2.75 equivalents of a non-nucleophilic base, such as DIPEA or TEA for about 30 min to about 1 h. About 3 equivalents of a suitable borohydride reducing agent, such as sodium borohydride, sodium tri(acetoxy)borohydride, or sodium cyanoborohydride, may be added, and the resulting mixture may be stirred at about RT for about 12 to 24 h. The resulting reaction product may be isolated by techniques well known in the art, such as extraction and column chromatography. For example, the reaction mixture may be quenched slowly with a saturated aqueous mild basic solution, such as Nal lCO;. The resulting mixture may be extracted with a suitable organic solvent, such as DCM or EtOAc, and the combined organic
extracts may be washed sequentially with water, saturated aqueous NaCl, dried over a suitable drying agent, such as NaiSCh or MgSCh, filtered, and the filtrate may be concentrated under reduced pressure. The resulting residue may be purified by flash chromatography over silica, using a suitable mixture of polar and non-polar organic solvents, such as EtOAc or acetone in hexanes, or methanol in DCM or EtOAc, to obtain the title compound.
Scheme 4 illustrates the synthesis of a compound of Formula I, wherein X = methyl: 1 -[2-[(3R,5 S)- 1 -[( 1 S)- 1 -(6-fluoro-2-m ethyl- 1 ,3 -benzothiazol-5-yl)ethyl]-5-methyl- pyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl]ethanone.
In Scheme 4, the substituted pyrrolidine as generated in Scheme 3, Step B, or its free base, is dissolved in a suitable solvent, such as acetonitrile, treated with about 0.8 equivalents of 5-[(lR)-l-chloroethyl]-6-fluoro-2-methyl-l,3-benzothiazole and excess cesium carbonate, and stirred for about 21 hours at about 68°C. The product of is then isolated and purified under conditions well known in the art.
Further Examples
Example 4 l-(2-(((3R,5S)-l-((6-fluoro-2-methylbenzo[d]thiazol-5-yl)methyl)-5-methylpyrrolidin-3- yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one
Scheme 3, step C: To a solution of 6-fluoro-2-methyl-l,3-benzothiazole-5- carbaldehyde (0.19 g, 0.95 mmol) and l-(2-(((3R,5S)-5-methylpyrrolidin-3-yl)oxy)-5,7- dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one hydrochloride (0.28 g, 0.94 mmol) in DCM (9 mb) is added DTPEA (0.45 mL, 2.6 mmol). The resulting solution is stirred at RT for 40 min. To the solution is added NaBH(OAc)3 (0.65 g, 3.04 mmol). The resulting solution is stirred at RT for 17 h. The reaction mixture is quenched slowly with saturated aqueous NaHCCh (5 mL). The aqueous layer is extracted with DCM (2 x 5 mL). The combined organic extracts are dried over MgSCh, filtered, and concentrated under reduced pressure. The resulting residue is dissolved in DCM and purified via flash chromatography over silica gel, eluting with a gradient of 40-100% acetone in hexanes, to obtain the title compound after solvent evaporation of the desired chromatographic fractions (0.27 g, 65% yield). ES/MS m/z 441 (M+H); [a]D 20 = +101.4° (c = 0.2, MeOH).
Example 5 l-[2-[(3R,5S)-l-[(lS)-l-(6-fluoro-2-methyl-l,3-benzothiazol-5-yl)ethyl]-5-methyl- pyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl]ethanone
Scheme 4: To a solution of l-(2-(((3R,5S)-5-methylpyrrolidin-3-yl)oxy)-5,7-dihydro-
6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one hydrochloride (0.192 g, 0.644 mmol) in acetonitrile (5.0 mL) is added 5-[(lR)-l-chloroethyl]-6-fluoro-2-methyl-l,3-benzothiazole (0.104 g, 0.452 mmol) and cesium carbonate (1.56 g, 4.79 mmol). The suspension is stirred at 65 °C for 17 h. The crude reaction is cooled to room temperature and filtered through celite. The filtrate is concentrated and purified via flash chromatography (silica gel) eluting with hexanes:(3:l acetone:DCM) [60:40 to 0:100], This material is further purified on a Chiralpak AD-H column with 40% MeOH(0.2% IPAm)/CO2 as the mobile phase to give 1- (2-(((3R,5S)-l-((S)-l-(6-fluoro-2-methylbenzo[d]thiazol-5-yl)ethyl)-5-methylpyrrolidin-3- yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-l-one (0.033 g, 0.073 mmol, 16% yield). MS w/z: 455 (M+H). [a]D 20 = +19.5 ° (c = 0.2, MeOH).
Claims
WE CLAIM:
(b) reacting the second compound with N,N-diisopropylethylamine and (2,4-dimethoxyphenyl)methanamine to yield a third compound
(c) reacting the third compound with anisole and an acid, and subsequently treating with base to yield the compound
The method according to claim 4, wherein the compound
reacted with acetic anhydride to yield a fourth compound
A method of synthesizing a compound:
comprising: reacting a first compound
p-toluenesulfonic anhydride ield the compound
The method according to claim 6, wherein the first compound is dissolved in 2- methyltetrahydrofuran and triethylamine.
8. The method according to claim 6, further comprising reacting the second compound with 2-nitrobenzenesulfonamide and an inorganic base to yield a third compound
9. The method according to claim 8, further comprising reacting the third compound with 1 -dodecanethiol and an inorganic base, and subsequently reacting with acetic anhydride, to yield the compound
10. A method of synthesizing a compound of Formula (I)
wherein X is hydrogen or methyl, comprising using the method of claim 4 or claim 5 to generate a reaction intermediate.
A method of synthesizing a compound of Formula (I)
wherein X is hydrogen or methyl, comprising using the method of any one of claims 6-9 to generate a reaction intermediate. A method of synthesizing a compound of Formula (I)
wherein X is hydrogen or methyl, wherein the method comprises an intermediate selected from the group consisting
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263416064P | 2022-10-14 | 2022-10-14 | |
US63/416,064 | 2022-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024081775A1 true WO2024081775A1 (en) | 2024-04-18 |
Family
ID=88779857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/076675 WO2024081775A1 (en) | 2022-10-14 | 2023-10-12 | Synthesis of 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024081775A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017031918A1 (en) * | 2015-08-24 | 2017-03-02 | 四川科伦药物研究院有限公司 | Long-acting dipeptidyl peptidase-iv inhibitor, applications, and preparation method for intermediate thereof |
US20170298082A1 (en) | 2014-08-28 | 2017-10-19 | Asceneuron Sa | Glycosidase inhibitors |
WO2018109202A1 (en) | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Monocyclic oga inhibitor compounds |
WO2018109198A1 (en) | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
WO2020068530A1 (en) | 2018-09-26 | 2020-04-02 | Eli Lilly And Company | 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds |
WO2021099284A1 (en) * | 2019-11-19 | 2021-05-27 | F. Hoffmann-La Roche Ag | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
-
2023
- 2023-10-12 WO PCT/US2023/076675 patent/WO2024081775A1/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170298082A1 (en) | 2014-08-28 | 2017-10-19 | Asceneuron Sa | Glycosidase inhibitors |
WO2017031918A1 (en) * | 2015-08-24 | 2017-03-02 | 四川科伦药物研究院有限公司 | Long-acting dipeptidyl peptidase-iv inhibitor, applications, and preparation method for intermediate thereof |
WO2018109202A1 (en) | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Monocyclic oga inhibitor compounds |
WO2018109198A1 (en) | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
WO2020068530A1 (en) | 2018-09-26 | 2020-04-02 | Eli Lilly And Company | 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds |
US10752632B2 (en) | 2018-09-26 | 2020-08-25 | Eli Lilly And Company | 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds |
US10836773B1 (en) | 2018-09-26 | 2020-11-17 | Eli Lilly And Company | 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds |
WO2021099284A1 (en) * | 2019-11-19 | 2021-05-27 | F. Hoffmann-La Roche Ag | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
Non-Patent Citations (8)
Title |
---|
E.L. ELIELS.H. WILEN: "Stereochemi try of Organic Compounds", 1994, WILEY |
GRAHAM ET AL., NEUROPHARMACOLOGY, vol. 79, 2014, pages 307 - 313 |
J. JACQUES ET AL.: "Enantiomer , Racemates, and Resolutions", 1981, JOHN WILEY AND SONS |
NELSON ET AL., J NEUROPATHOLEXP NEUROL., vol. 71, no. 5, 2012, pages 362 - 381 |
T. A. BERGER: "Supercritical Fluid Chromatography Primer", July 2015, AGILENT TECHNOLOGIES |
WILLIAMS ET AL., BRAIN, vol. 130, 2007, pages 1566 - 76 |
YUZWA ET AL., NAT CHEM BIOL, vol. 4, no. 8, 2008, pages 483 - 490 |
YUZWA ET AL., NAT CHEM BIOL, vol. 8, 2012, pages 393 - 399 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6717457B2 (en) | 1,2-Dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivatives as Wee1 inhibitors | |
IL281726B2 (en) | Manufacture of compounds and compositions for inhibiting the activity of shp2 | |
US20130158265A1 (en) | Sitagliptin, salts and polymorphs thereof | |
KR20210059801A (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetr-ahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
KR20070112255A (en) | Process for the preparation of opioid modulators | |
KR20180025940A (en) | 7H-pyrrolo [2,3-d] pyrimidine derivatives and intermediates therefor | |
CN102317289A (en) | Lactams as beta secretase inhibitors | |
CA2908963A1 (en) | Perhydroquinoxaline derivatives useful as analgesics | |
AU2018448845B2 (en) | Method for producing dimethoxybenzene compound | |
TWI716107B (en) | 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds | |
WO2014068341A2 (en) | Chiral fluorinating reagents | |
WO2024081775A1 (en) | Synthesis of 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds | |
KR20170105021A (en) | Method for producing pyrazine carboxamide compound, and synthetic intermediate thereof | |
JP4368304B2 (en) | Process for the preparation of amino-pyrrolidine derivatives | |
US7759491B2 (en) | Method for producing indazol-3-ylmethyl phosphonium salt | |
WO2016079109A1 (en) | Process for the preparation of perhydroquinoxaline derivatives | |
CN114341155A (en) | Preparation method of peptide amide compound and intermediate thereof | |
Sánchez et al. | Synthesis of 5-N-acetylardeemin seco-analogues | |
CA3108158C (en) | 5-methyl-4-fluoro-thiazol-2-yl compounds | |
CN116102500A (en) | Method for synthesizing 6-chloro-2-methyl-2H-indazole-5-amine | |
JPH107652A (en) | Production of pyrrolidine derivative | |
JPH07149729A (en) | 1,2,3,4-tetrahydroquinoline-8-sulfonic acid, its chloride, their preparation and their use as synthesis intermediates | |
WO2021083554A1 (en) | 3-((r)-2-(amino-2-phenylethyl)-1-(2-fluoro-6-trifluoromethyl benzyl)-5-iodo-6-methyl-1h-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix | |
TW202400166A (en) | Method of preparing compound for cftr activator and intermediate used therein | |
KR20190055775A (en) | New benzimidazole derivatives as dual histamine h1 and histamine h4 receptor ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23805361 Country of ref document: EP Kind code of ref document: A1 |